Sign in to continue:

Saturday, March 7th, 2026

Genesco Inc. Reports Strong Fiscal 2026 Q4 and Full Year Results: Journeys Leads with Double-Digit Sales Growth, Operating Income Up 24%





Genesco Inc. Fiscal 2026-2027 Financial Results and Outlook: Detailed Investor Report

Genesco Inc. Releases Fiscal 2026 Results and Fiscal 2027 Outlook: Key Takeaways for Investors

Summary of Fiscal 2026 Results

  • Net Sales: \$2.44 billion for the fiscal year ended January 31, 2026, up from \$2.33 billion in the prior year, representing growth despite sector challenges.
  • Gross Margin: Reported at 46.3% versus 47.2% in the previous year. The drop was partly due to a \$1.3 million inventory write-down related to license exits in the Genesco Brands Group and a \$1.8 million charge in the prior year for a distribution model transition.
  • Operating Income: Improved to \$17.3 million (0.7% of sales) from \$13.9 million (0.6% of sales) the prior year, despite \$8.1 million in charges for store restructuring, IT transformation, asset impairments, and severance.
  • Net Earnings: \$13.27 million (0.5% of sales) compared to a net loss of \$18.89 million (-0.8%) in the prior year. This swing to profitability is notable for investors.
  • Adjusted Earnings from Continuing Operations (Non-GAAP): \$15.37 million (\$1.45 per share) for FY26, up from an adjusted loss of \$(17.03) million (\$(1.57) per share) in FY25.
  • Cash and Share Repurchase: The company had \$29.8 million remaining under its expanded share repurchase authorization as of June 2023, signaling ongoing commitment to capital return.

Segment Performance Highlights

  • Journeys Group: Sales increased to \$1.49 billion (61.4% of net sales), with operating income rising sharply to \$60.5 million (4.0% margin) from \$26.3 million (1.9%). This segment’s strong recovery was a key driver of overall performance.
  • Schuh Group: Sales grew to \$500 million (20.5%), but operating income fell to a loss of \$(4.5) million (-0.9%), compared to a \$10.2 million profit last year. However, management is optimistic about margin recovery as the business shifts back to full-price selling.
  • Johnston & Murphy Group: Sales reached \$126 million (5.0%) with an operating profit of \$4.6 million (1.4%), down slightly from last year.
  • Genesco Brands Group: Sales dropped to \$104 million (4.3%), with a widened operating loss of \$(37.8) million (-1.6%) due to license exits and inventory write-downs.

Key One-Off and Non-Recurring Items

  • Inventory Write-Down: \$1.3 million charge in Genesco Brands Group for license exits.
  • Store Restructuring and IT Transformation: Total charges of \$8.1 million, including \$3.9 million for store restructuring and \$2.9 million for IT transformation.
  • U.S. Valuation Allowance: The prior year included a \$26.2 million income tax expense related to a U.S. valuation allowance, which did not recur in FY26.
  • Tax Impact of “One Big Beautiful Bill Act”: Reported an \$11.9 million tax benefit in Q4 FY26.
  • Visa/Mastercard Interchange Fee Settlement: A forecasted gain of \$9.4 million (\$0.86 per share) included in FY27 guidance.

Fiscal 2027 Outlook: Guidance and Investor Considerations

  • Comparable Sales: Expected to grow 1-2%. However, total sales are projected to be flat to down 1% due to a \$30 million reduction each from license exits and net store closures.
  • Adjusted Diluted EPS Guidance: \$1.90 to \$2.30 for FY27 (based on 10.9 million shares outstanding). This guidance excludes non-recurring items and assumes no further share repurchases.
  • Tax Rate: Guidance assumes a full-year tax rate of 30%, but due to the valuation allowance, the rate for the first three quarters will be 7-8%.
  • Profitability Drivers: Projected improvement in bottom line due to further margin recovery at Journeys, a turnaround at Johnston & Murphy, and improved Schuh profitability with a focus on returning to full price, full margin sales.
  • Share Repurchase: Guidance does not include the impact of any additional buybacks. \$29.8 million remains on the current repurchase authorization, which could be deployed to enhance EPS.
  • Non-GAAP Adjusted Guidance: Guidance excludes \$2.8 million net charges for asset impairments and one-off settlement gains, providing a clearer view of underlying performance.

Risks and Forward-Looking Statements

  • Key Risks: The company highlights risks including consumer spending weakness, e-commerce and mall traffic trends, cost inflation, supply chain disruptions (including geopolitical events and tariffs), wage and labor pressures, IT restructuring impacts, and exposure to changing tax laws and litigation.
  • Market Sensitivities: The forward guidance is highly sensitive to consumer trends, promotional intensity, execution of store closures and openings, and realization of cost savings from IT transformation and store optimization.
  • Impairments and Restructuring: Failure to achieve expected digital gains, cost savings, or successful execution of omnichannel initiatives could lead to further impairments or charges.
  • External Factors: Ongoing conflicts (Russia-Ukraine, Middle East), regulatory changes, and the evolving retail landscape could materially affect results.

Potential Share Price Impacts and Investor Takeaways

  • Swing to Profitability: The return to profitability and positive adjusted EPS after a loss in the prior year is a potential catalyst for share price appreciation.
  • Margin Recovery Story: Improvement in core segments, especially Journeys and Schuh, could drive positive sentiment if sustained.
  • Share Buybacks: The \$29.8 million remaining for repurchases could provide support for the stock or boost EPS if deployed.
  • Execution Risks: Investors should monitor how well management executes on store closures, cost control, and the transition to higher-margin, full-price sales.
  • One-Off Gains: Adjusted outlook excludes Visa/Mastercard settlement and non-recurring charges, which may obscure underlying trends versus reported results.
  • Tax Rate Volatility: The significant swing in tax rates between quarters could drive quarterly EPS volatility.

Conclusion

Genesco Inc.’s Fiscal 2026 results show a solid turnaround, with a swing back to profitability, improved performance at Journeys, and plans to further boost margins and earnings in Fiscal 2027. The company is actively restructuring, exiting low-performing licenses, and investing in IT and omnichannel capabilities. However, the outlook remains cautious due to ongoing industry and macroeconomic risks, and investors should closely monitor execution on key initiatives and external market factors. The remaining share repurchase authorization and non-GAAP adjustments are important levers that could affect future EPS and share price.


Disclaimer: This article is a summary and interpretation of Genesco Inc.’s financial report for the benefit of investors. It is not investment advice. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should conduct their own due diligence and review the company’s filings with the SEC for further information.




View GENESCO INC Historical chart here



Cal-Maine Foods Acquires Creighton Brothers LLC and Crystal Lake for $128.5 Million, Expanding Egg Production and Geographic Reach 1

Cal-Maine Foods Announces Strategic Acquisition of Creighton Brothers and Crystal Lake Key Points for Investors Acquisition Value: Cal-Maine Foods (NASDAQ: CALM) acquires Creighton Brothers LLC and Crystal Lake LLC for approximately \$128.5 million, funded...

Duos Technologies Group, Inc. Files Form 8-K Current Report with Financials and Company Details (Feb 26, 2026)

Duos Technologies Group, Inc. Reports Preliminary 2025 Full-Year Results Duos Technologies Group, Inc. Reports Preliminary 2025 Full-Year Results Key Points from the SEC Form 8-K Filing Dated March 4, 2026 Highlights of the Preliminary...

American Healthcare REIT, Inc. (AHR) 2025 Annual Report: Real Estate Portfolio, Financials, and Business Overview

American Healthcare REIT 2025 Annual Report – Investor Insights American Healthcare REIT 2025 Annual Report: Key Highlights and Investor Insights American Healthcare REIT, Inc. (AHR) has released its Form 10-K for the fiscal year...

   Ad